Please assess the completion status of the following clinical trial:

Trial Title: Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects ≥ 18 years of age~* Aneurysmal subarachnoid hemorrhage, proven on CT angiogram or digital subtraction angiography~* Aneurysm treated, either by endovascular embolization or surgical clip ligation~* Evidence of increased velocities on transcranial dopplers (TCDs) and/or radiographic evidence of vasospasm as seen on angiogram~* Cerebral vasospasm as demonstrated by patient's clinical exam (new focal deficit or change in mental status not attributable to any other cause)~Exclusion Criteria:~* Recurrent subarachnoid hemorrhage~* Untreated ruptured aneurysm, for any reason~* Patients who die prior to treatment for aneurysm~* Patients who are not able to complete at least 6 months of follow-up~* Patients who are admitted already in vasospasm (i.e. a delayed admission)~* Creatinine clearance less than 20 ml/min~* Women with a positive pregnancy test or who are lactating~* Other comorbidity which may adversely affect patient outcome, at the discretion of the principal investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Milrinone (Type: ACTIVE_COMPARATOR): Milrinone will be administered intravenously at an initial rate of 0.75mCg/kg/min and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (Normal Saline) will be administered intravenously and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).